Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 2
1973 2
1998 2
2000 1
2002 1
2007 1
2008 1
2009 3
2011 1
2017 4
2018 5
2019 6
2020 1
2021 1
2022 4
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Genomic landscape of TP53-mutated myeloid malignancies.
Abel HJ, Oetjen KA, Miller CA, Ramakrishnan SM, Day RB, Helton NM, Fronick CC, Fulton RS, Heath SE, Tarnawsky SP, Nonavinkere Srivatsan S, Duncavage EJ, Schroeder MC, Payton JE, Spencer DH, Walter MJ, Westervelt P, DiPersio JF, Ley TJ, Link DC. Abel HJ, et al. Among authors: oetjen ka. Blood Adv. 2023 Aug 22;7(16):4586-4598. doi: 10.1182/bloodadvances.2023010156. Blood Adv. 2023. PMID: 37339484 Free PMC article.
Immunological effects of hypomethylating agents.
Lindblad KE, Goswami M, Hourigan CS, Oetjen KA. Lindblad KE, et al. Among authors: oetjen ka. Expert Rev Hematol. 2017 Aug;10(8):745-752. doi: 10.1080/17474086.2017.1346470. Epub 2017 Jul 3. Expert Rev Hematol. 2017. PMID: 28644756 Free PMC article. Review.
Genomic landscape of TP53 -mutated myeloid malignancies.
Abel HJ, Oetjen KA, Miller CA, Ramakrishnan SM, Day RB, Helton NM, Fronick CC, Fulton RS, Heath SE, Tarnawsky SP, Srivatsan SN, Duncavage EJ, Schroeder MC, Payton JE, Spencer DH, Walter MJ, Westervelt P, DiPersio JF, Ley TJ, Link DC. Abel HJ, et al. Among authors: oetjen ka. medRxiv [Preprint]. 2023 Jan 11:2023.01.10.23284322. doi: 10.1101/2023.01.10.23284322. medRxiv. 2023. PMID: 36711871 Free PMC article. Updated. Preprint.
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.
Goswami M, Gui G, Dillon LW, Lindblad KE, Thompson J, Valdez J, Kim DY, Ghannam JY, Oetjen KA, Destefano CB, Smith DM, Tekleab H, Li Y, Dagur P, Hughes T, Marté JL, Del Rivero J, Klubo-Gwiezdzinksa J, Gulley JL, Calvo KR, Lai C, Hourigan CS. Goswami M, et al. Among authors: oetjen ka. J Immunother Cancer. 2022 Jan;10(1):e003392. doi: 10.1136/jitc-2021-003392. J Immunother Cancer. 2022. PMID: 35017151 Free PMC article.
36 results